VaxInnate, a US-based biotechnology firm, has received a grant from the National Institute of Allergy and Infectious Diseases (NIAID) to fund the development of a recombinant vaccine for the prevention of dengue.
The grant will provide $2.2m over three years to develop a recombinant tetravalent dengue vaccine using VaxInnate's proprietary technology, which includes genetically fusing vaccine antigens to the bacterial protein flagellin.
VaxInnate president and CEO Wayne Pisano said that the company is pleased to receive the grant and look forward to work with NIAID to develop a vaccine to prevent dengue.
The NIAID grant is VaxInnate's fourth funding opportunity from the US Government.
VaxInnate is using recombinant technology to develop pandemic and seasonal influenza vaccines under the 2011 contract with the Biomedical Advanced Research and Development Authority (BARDA), part of the US department of Health and Human Services (HHS).
NIAID, which is a part of the US National Institutes of Health (NIH), conducts and supports research to understand, treat and prevent infectious, immunologic and allergic diseases.
